PainInvestigational

Conantokin-G

Intrathecal, Intravenous

Overview

Conantokin-G is a 17-amino acid peptide originally isolated from the venom of the cone snail Conus geographus. It acts as a selective antagonist of N-methyl-D-aspartate (NMDA) receptors containing the NR2B subunit, which are implicated in chronic pain, neuropathic pain, and central sensitization.

Mechanism of Action

The peptide contains gamma-carboxyglutamic acid residues that are critical for its activity and metal ion binding. Conantokin-G represents a novel class of non-opioid analgesics targeting glutamatergic neurotransmission..

Research Summary & Key Findings

Preclinical studies have demonstrated analgesic and neuroprotective effects of conantokin-G in rodent models of neuropathic pain, epilepsy, and ischemic injury. The peptide showed promise in early safety and pharmacokinetic studies, but clinical development has been limited. Challenges include synthesis complexity, delivery to the central nervous system, and limited clinical trial data in pain populations.

Clinical Status

Investigational

Conantokin-G is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

IntrathecalIntravenous

Related Peptides in Pain

Find a Provider

Find a verified provider who offers Conantokin-G therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Conantokin-G.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.